Log In
Print
BCIQ
Print
Print this Print this
 

INN-329 (formerly RG1068, SecreFlo)

Also known as: secretin

  Manage Alerts
Collapse Summary General Information
Company Innovate Biopharmaceuticals Inc.
DescriptionSynthetic human secretin
Molecular Target Unknown
Mechanism of Action 
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationGastrointestinal, Diagnostic
Indication DetailsAid in functional MRI of the pancreas; Help in the location and cannulation of the minor pancreatic duct in patients with pancreas divisum; Improve detection and characterization of pancreatic cancer in combination with MRI; Improve detection of pancreatic duct abnormalities in combination with MRI; Improve detection of structural abnormalities of the pancreatic ducts during magnetic resonance imaging (MRI); Stimulate pancreatic secretions to aid in diagnosis of pancreatic exocrine dysfunction
Regulatory Designation

U.S. - Fast Track (Improve detection of structural abnormalities of the pancreatic ducts during magnetic resonance imaging (MRI));
U.S. - Orphan Drug (Improve detection of structural abnormalities of the pancreatic ducts during magnetic resonance imaging (MRI));
U.S. - Priority Review (Improve detection of structural abnormalities of the pancreatic ducts during magnetic resonance imaging (MRI))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today